antibody

Polyclonal Antibody to Procollagen I N-Terminal Propeptide (PINP)

MBS2085980

0.01 mg

115 USD

polyclonal

rabbit

nonconjugated

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

Antibody

Polyclonal Antibody to Procollagen I N-Terminal Propeptide (PINP)

[Procollagen I N-Terminal Propeptide (PINP)]

[P1NP; N-Propeptide Of Type I Procollagen; Procollagen I Amino Terminal Propeptide]

[collagen alpha-1(I) chain preproprotein; Collagen alpha-1(I) chain; collagen alpha-1(I) chain; collagen type I alpha 1 chain; Alpha-1 type I collagen]

[PINP]

[COL1A1; COL1A1; OI1; OI2; OI3; OI4; EDSC]

Polyclonal

Rabbit

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

0.55mg/ml

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: . The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Western blot (WB); Immunohistochemistry (IHC); Immunocytochemistry (ICC); Immunoprecipitation (IP)

Western blotting: 0.5-2ug/mL;1:270-1100. Immunohistochemistry: 5-20ug/mL;1:27-110. Immunocytochemistry: 5-20ug/mL;1:27-110. Optimal working dilutions must be determined by end user

Western Blot (WB)

Organism Species: Homo sapiens (Human). Source: Polyclonal antibody preparation. Traits: Liquid

Immunogen: Synthetic Peptide, PINP conjugated to OVA. Target peptide sequence: CPDGSESPTDQETTGV

110349772

NP_000079.2

NM_000088.3

P02452

Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Assembly Of Collagen Fibrils And Other Multimeric Structures Pathway (730306); Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Collagen Biosynthesis And Modifying Enzymes Pathway (645289); Collagen Formation Pathway (645288); ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Extracellular Matrix Organization Pathway (576262); Focal Adhesion Pathway (198795)

This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon. Mutations in this gene are associated with osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the growth factor. Two transcripts, resulting from the use of alternate polyadenylation signals, have been identified for this gene. [provided by R. Dalgleish, Feb 2008]

COL1A1: Type I collagen is a member of group I collagen (fibrillar forming collagen). Defects in COL1A1 are the cause of Caffey disease (CAFFD); also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age. Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1); also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome. Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A); also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations. Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1). A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 2 (OI2); also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency. Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3). A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4); also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta. Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP); also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture. A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF. Belongs to the fibrillar collagen family. Protein type: Extracellular matrix; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 17q21.33. Cellular Component: collagen type I trimer; endoplasmic reticulum lumen; extracellular matrix; extracellular region; extracellular space; Golgi apparatus; secretory granule. Molecular Function: extracellular matrix structural constituent; identical protein binding; metal ion binding; platelet-derived growth factor binding; protease binding; protein binding. Biological Process: blood coagulation; blood vessel development; cellular response to epidermal growth factor stimulus; cellular response to fibroblast growth factor stimulus; cellular response to fluoride; cellular response to retinoic acid; cellular response to transforming growth factor beta stimulus; cellular response to tumor necrosis factor; cellular response to vitamin E; collagen biosynthetic process; collagen catabolic process; collagen fibril organization; collagen-activated tyrosine kinase receptor signaling pathway; embryonic skeletal system development; endochondral ossification; extracellular matrix organization; intramembranous ossification; leukocyte migration; negative regulation of cell-substrate adhesion; osteoblast differentiation; platelet activation; positive regulation of canonical Wnt signaling pathway; positive regulation of cell migration; positive regulation of epithelial to mesenchymal transition; positive regulation of transcription, DNA-templated; protein localization to nucleus; protein transport; regulation of immune response; response to cAMP; response to corticosteroid stimulus; response to drug; response to estradiol; response to hydrogen peroxide; response to hyperoxia; response to peptide hormone; sensory perception of sound; skeletal system development; skin morphogenesis; tooth eruption; tooth mineralization; visual perception. Disease: Caffey Disease; Ehlers-danlos Syndrome, Type I; Ehlers-danlos Syndrome, Type Vii, Autosomal Dominant; Osteogenesis Imperfecta, Type I; Osteogenesis Imperfecta, Type Ii; Osteogenesis Imperfecta, Type Iii; Osteogenesis Imperfecta, Type Iv; Osteoporosis

0.01 mg

115 USD

0.02 mg

135

0.05 mg

195

0.1 mg

250

0.2 mg

385

1 mg

910